Table 1 Baseline characteristics of the study participants

No. of subjects

85

50

25

7

5

10

No. of eyes

162

87

41

11

7

15

Gender^a

0.0012^†

 Female

63 (74%)

21 (42%)

10 (42%)

2 (33%)

2 (50%)

7 (78%)

 Male

22 (26%)

29 (58%)

14 (58%)

4 (67%)

2 (50%)

2 (22%)

Age, y

51.12 ± 13.06

51.38 ± 12.13

56.72 ± 9.37

54.71 ± 14.42

44.80 ± 4.55

58.07 ± 9.04

0.656

MAP, mmHg

101.76 ± 8.67

103.03 ± 13.57

105.68 ± 12.90

106.28 ± 13.09

107.08 ± 18.86

101.70 ± 12.91

0.239

VA, logMAR

0.04 ± 0.06

0.15 ± 0.17

0.16 ± 0.17

0.28 ± 0.29

0.55 ± 0.31

0.16 ± 0.12

< 0.0001

OPP, mmHg

52.06 ± 6.47

52.48 ± 9.32

55.35 ± 8.60

55.12 ± 8.61

55.90 ± 11.53

55.40 ± 7.76

0.312

DM duration, m

–

78.38 ± 69.51

138.80 ± 87.17

140.00 ± 106.97

72.06 ± 56.18

168.25 ± 126.46

0.0159

Hypertension

–

20 (40%)

15 (60%)

3 (42%)

2 (40%)

6 (60%)

0.4706^†

Diabetic nephropathy

–

6 (6%)

2 (8%)

1 (14%)

1 (20%)

1 (10%)

0.4611^†

HbA1c, %

–

8.42 ± 2.07

8.03 ± 1.53

9.34 ± 0.80

10.04 ± 0

8.56 ± 1.77

0.2477